Forte Biosciences, Inc. Overview
Pro stress-test →Forte Biosciences is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The company's lead candidate, FB-102, is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.
Strategic Profile
Pro stress-test →FB102 received Fast Track Designation from the FDA in celiac disease, highlighting the unmet need. Based on the strength of the positive results from the FB102 phase 1b CeD trial, which was reported in June 2025, the company looks forward to the phase 2 data further validating FB102 for the treatment of celiac disease. The company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
Competitive Landscape
Pro stress-test →FB102 faces a crowded competitive landscape with 14+ rival programs in development for celiac disease. The company competes in the autoimmune therapeutic space against both established biologics manufacturers and other clinical-stage immunology companies targeting similar pathways and indications.
Industry Context
Forte Biosciences, Inc. operates in Clinical-stage immunology therapeutics.
Key facts
Founded: Not specified in available sources · Headquarters: Dallas, Texas, US · Employees: Not disclosed · Revenue: N/A (pre-revenue, clinical stage) · Market cap: $325M (as of June 5, 2026)